Investors eyeing the primary markets should take note: Gujarat Kidney & Super Speciality is gearing up to launch its

initial public offering (IPO) next week. The subscription window for this multispeciality healthcare provider's IPO

opens on Monday, December 22, 2025, as the company seeks to raise capital from the Indian stock market.

Operating out of Gujarat, the firm delivers secondary and tertiary medical services across a network of locations within

the state. Their infrastructure includes seven multispeciality hospitals and four pharmacies, totaling around 490 beds.

Here's a breakdown of 10 essential details gleaned from the company's Red Herring Prospectus (RHP):

* **IPO Dates:** The offering will be available to investors from December 22nd to December 24th, 2025.

* **Offer Specifics:** The IPO consists entirely of a fresh issue of up to 22,000,000 equity shares, each with a face

value of ₹2, according to the RHP. The company has not yet disclosed the total funds it aims to generate through this

offering.

* **Utilization of Funds:** Gujarat Kidney intends to allocate ₹77 crore towards acquiring Parekhs Hospital in

Ahmedabad. Furthermore, ₹12.40 crore is earmarked for partially covering the purchase of Ashwini Medical Centre. The RHP

reveals plans to invest ₹10.78 crore in acquiring additional shares of Harmony Medicare Pvt. Ltd, a subsidiary. An

investment of ₹30.09 crore is also planned to meet the capital expenditure for establishing a new hospital in Vadodara.

Additionally, ₹6.82 crore is set aside for purchasing robotics equipment, and ₹1.20 crore for debt repayment. The

remaining capital will be used for general business needs.

* **Price Range:** The company has set the IPO's price range between ₹108 and ₹114 per share. Investors can bid in lots

of 128 shares.

* **Anchor Investors:** The anchor investor bidding took place on Friday, December 19, 2025.

* **Investor Allocation:** Not less than 75% of the offering is reserved for Qualified Institutional Buyers (QIBs). No

more than 15% is allocated to Non-Institutional Investors (NIIs), and a maximum of 10% is designated for retail

investors.

* **Book Running and Registrar:** Nirbhay Capital Services is managing the IPO, acting as the book-running lead manager.

MUFG Intime India Pvt. Ltd (formerly Link Intime India Pvt. Ltd) is the registrar for the offering.

* **Grey Market Premium (GMP):** As of Saturday, December 20, 2025, the grey market premium for Gujarat Kidney's IPO was

₹7 per share. Based on the upper price band of ₹114, the stock is anticipated to list at ₹121 per share, representing a

potential premium of 6%, according to IPO India data. The grey market premium reflects investor sentiment towards the

IPO.

* **Profit Performance:** The company reported a net profit of ₹5.40 crore for the April-June quarter of fiscal year

2025-26, according to the RHP. Profits were ₹9.49 crore for fiscal year 2024-25 and ₹1.71 crore for fiscal year 2023-24.

* **Revenue Figures:** The company's revenue from operations was ₹15.26 crore for the April-June quarter of fiscal year

2025-26. Revenue stood at ₹40.24 crore for fiscal year 2024-25 and ₹4.77 crore for fiscal year 2023-24.

*Disclaimer: This article is intended for informational purposes only and should not be considered investment advice.

Consult with a qualified financial advisor before making any investment decisions.*